Antihistaminic drug olopatadine downmodulates CCL17/TARC production by keratinocytes and Langerhans cells.

@article{Sugita2009AntihistaminicDO,
  title={Antihistaminic drug olopatadine downmodulates CCL17/TARC production by keratinocytes and Langerhans cells.},
  author={Kazunari Sugita and Miwa Kobayashi and Tomoko Mori and Kenji Kabashima and Motonobu Nakamura and Yoshiki Tokura},
  journal={The Journal of dermatology},
  year={2009},
  volume={36 12},
  pages={
          654-7
        }
}
  • Kazunari Sugita, Miwa Kobayashi, +3 authors Yoshiki Tokura
  • Published 2009
  • Medicine
  • The Journal of dermatology
  • Dear Editor, Olopatadine hydrochloride (OLP; [Z]-11-[3-dimethylaminopropylidene]-6,11dihydrodinenz [b,e] oxepin-2acetic acid monohydrochloride) is a histamine H1-receptor-blockingagentthatpossessesbothacidic and basic residues. This H1 blocker also suppresses the production by epithelial cells or mast cells of various chemical mediators and cytokines, such as leukotrienes, arachidonic acid, interleukin (IL)-6, IL-8 and tumor necrosis factor-a (TNF-a), and inhibits intracellular adhesion… CONTINUE READING

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 22 REFERENCES

    Olopatadine inhibits TNFalpha release from human conjunctival mast cells.

    Olopatadine inhibits anti-immunoglobulin E-stimulated conjunctival mast cell upregulation of ICAM-1 expression on conjunctival epithelial cells.